Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 4/20 | 0.44 |
| ▸ | BACE1 | P56817 | 3/20 | 0.44 |
| ▸ | JAK2 | O60674 | 6/20 | 0.44 |
| ▸ | AURKA | O14965 | 3/20 | 0.43 |
| ▸ | PLK4 | O00444 | 2/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
| ▸ | PRKCG | P05129 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | LYN | P07948 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30086842 | 1.00 | GSK3B (0.47) | GSK3BACHEBACE1JAK2AURKA | |
| SCHEMBL30086679 | 0.94 | GSK3B (0.56) | GSK3BJAK2AURKAPLK4MAPT | |
| SCHEMBL23906206 | 0.94 | GSK3B (0.56) | GSK3BJAK2AURKAPLK4MAPT | |
| SCHEMBL30086921 | 0.93 | JAK2 (0.52) | JAK2AURKAPLK4LYNKIT | |
| SCHEMBL23906923 | 0.93 | JAK2 (0.52) | JAK2AURKAPLK4LYNKIT | |
| SCHEMBL25702920 | 0.92 | JAK2 (0.51) | GSK3BJAK2CDK1CDK2JAK3 | |
| SCHEMBL23906919 | 0.91 | ABL1 (0.48) | GSK3BJAK2AURKAPLK4LYN | |
| SCHEMBL23906686 | 0.91 | CDK6 (0.44) | GSK3BJAK2PLK4CDK1LYN | |
| SCHEMBL23906827 | 0.91 | JAK2 (0.41) | GSK3BJAK2PLK4LYNKIT | |
| SCHEMBL23906691 | 0.91 | JAK2 (0.41) | GSK3BJAK2PLK4LYNKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-11673879-B2 | Substituted pyrimidines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673879-B2 | Substituted pyrimidines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-13 | — | — | US | disclosed |
| WO-2021203131-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673879-B2 | Substituted pyrimidines and methods of use | ALK, TYMP, ENTPD5 | GSK3B 1144/4885ACHE 4551/4885BACE1 4004/4885 |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | ALK, TYMP, ENTPD5 | GSK3B 1144/4885ACHE 4551/4885BACE1 4004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.